{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:26:03Z","timestamp":1795116363225,"version":"4.10.3"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41581-025-00980-z","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T17:56:36Z","timestamp":1753120596000},"page":"653-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Antigens in membranous nephropathy: discovery and clinical implications"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-7709","authenticated-orcid":false,"given":"Sanjeev","family":"Sethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-209X","authenticated-orcid":false,"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"980_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","volume":"12","author":"WG Couser","year":"2017","unstructured":"Couser, W. G. Primary membranous nephropathy. Clin. J. Am. Soc. Nephrol. 12, 983\u2013997 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"980_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco, P. et al. Membranous nephropathy. Nat. Rev. Dis. Primers\u00a07, 69 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"980_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","volume":"104","author":"S Sethi","year":"2023","unstructured":"Sethi, S. et al. Mayo clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney Int. 104, 1092\u20131102 (2023).","journal-title":"Kidney Int."},{"key":"980_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck, L. H. et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11\u201321 (2009).","journal-title":"N. Engl. J. Med."},{"key":"980_CR5","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","volume":"371","author":"NM Tomas","year":"2014","unstructured":"Tomas, N. M. et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N. Engl. J. Med. 371, 2277\u20132287 (2014).","journal-title":"N. Engl. J. Med."},{"key":"980_CR6","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.mayocp.2023.08.006","volume":"98","author":"S Sethi","year":"2023","unstructured":"Sethi, S. et al. Mayo clinic consensus report on membranous nephropathy: proposal for a novel classification. Mayo Clin. Proc. 98, 1671\u20131684 (2023).","journal-title":"Mayo Clin. Proc."},{"key":"980_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1681\/ASN.2018080852","volume":"30","author":"S Sethi","year":"2019","unstructured":"Sethi, S. et al. Exostosin 1\/exostosin 2-associated membranous nephropathy. J. Am. Soc. Nephrol. 30, 1123\u20131136 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","volume":"97","author":"S Sethi","year":"2020","unstructured":"Sethi, S. et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 97, 163\u2013174 (2020).","journal-title":"Kidney Int."},{"key":"980_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","volume":"98","author":"S Sethi","year":"2020","unstructured":"Sethi, S. et al. Semaphorin 3B\u2013associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. 98, 1253\u20131265 (2020).","journal-title":"Kidney Int."},{"key":"980_CR10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1681\/ASN.2020081165","volume":"32","author":"S Sethi","year":"2021","unstructured":"Sethi, S. et al. Protocadherin 7-associated membranous nephropathy. J. Am. Soc. Nephrol. 32, 1249\u20131261 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1681\/ASN.2021111488","volume":"33","author":"S Sethi","year":"2022","unstructured":"Sethi, S. et al. Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1. J. Am. Soc. Nephrol. 33, 1033\u20131044 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.kint.2020.09.016","volume":"100","author":"TN Caza","year":"2021","unstructured":"Caza, T. N. et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. Kidney Int. 100, 171\u2013181 (2021).","journal-title":"Kidney Int."},{"key":"980_CR13","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1681\/ASN.2020101395","volume":"32","author":"LF Al-Rabadi","year":"2021","unstructured":"Al-Rabadi, L. F. et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy. J. Am. Soc. Nephrol. 32, 1666\u20131681 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR14","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.kint.2021.08.014","volume":"100","author":"M Le Quintrec","year":"2021","unstructured":"Le Quintrec, M. et al. Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. Kidney Int. 100, 1240\u20131249 (2021).","journal-title":"Kidney Int."},{"key":"980_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1017\/cjn.2020.46","volume":"47","author":"S Nazarali","year":"2020","unstructured":"Nazarali, S., Mathey, E. K., Tang, D., Margetts, P. J. & Baker, S. K. Chronic inflammatory demyelinating polyneuropathy and concurrent membranous nephropathy. Can. J. Neurol. Sci. 47, 585\u2013587 (2020).","journal-title":"Can. J. Neurol. Sci."},{"key":"980_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.kint.2023.04.006","volume":"104","author":"S Sethi","year":"2023","unstructured":"Sethi, S. et al. Proprotein convertase subtilisin\/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use. Kidney Int. 104, 343\u2013352 (2023).","journal-title":"Kidney Int."},{"key":"980_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1681\/ASN.0000000000000061","volume":"34","author":"S Sethi","year":"2023","unstructured":"Sethi, S. et al. Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor. J. Am. Soc. Nephrol. 34, 374\u2013384 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR18","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1681\/ASN.2022050608","volume":"33","author":"L Reinhard","year":"2022","unstructured":"Reinhard, L. et al. Netrin G1 is a novel target antigen in primary membranous nephropathy. J. Am. Soc. Nephrol. 33, 1823\u20131831 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.kint.2015.12.041","volume":"89","author":"T Lee","year":"2016","unstructured":"Lee, T. et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int. 89, 1111\u20131118 (2016).","journal-title":"Kidney Int."},{"key":"980_CR20","unstructured":"Ehrenreich, T. & Churg, J. in Pathology of Membranous Nephropathy 389\u2013433 (Appleton-Century-Crofts, 1968)."},{"key":"980_CR21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2024.08.009","volume":"106","author":"S Sethi","year":"2024","unstructured":"Sethi, S. et al. FAT1 is a target antigen in a subset of de novo allograft membranous nephropathy associated with antibody mediated rejection. Kidney Int. 106, 985\u2013990 (2024).","journal-title":"Kidney Int."},{"key":"980_CR22","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.ekir.2024.04.041","volume":"9","author":"K Tominaga","year":"2024","unstructured":"Tominaga, K. et al. Myeloperoxidase-associated membranous nephropathy in antineutrophil cytoplasmic antibody-associated glomerulonephritis. Kidney Int. Rep. 9, 2240\u20132249 (2024).","journal-title":"Kidney Int. Rep."},{"key":"980_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.kint.2023.01.001","volume":"103","author":"TN Caza","year":"2023","unstructured":"Caza, T. N. et al. Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry. Kidney Int. 103, 593\u2013606 (2023).","journal-title":"Kidney Int."},{"key":"980_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.kint.2023.01.003","volume":"103","author":"S Sethi","year":"2023","unstructured":"Sethi, S. & Madden, B. Mapping antigens of membranous nephropathy: almost there. Kidney Int. 103, 469\u2013472 (2023).","journal-title":"Kidney Int."},{"key":"980_CR25","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.34067\/KID.0001492021","volume":"2","author":"TN Caza","year":"2021","unstructured":"Caza, T. N. et al. Transforming growth factor beta receptor 3 (TGFBR3)-associated membranous nephropathy. Kidney360 2, 1275\u20131286 (2021).","journal-title":"Kidney360"},{"key":"980_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.kint.2024.07.031","volume":"106","author":"JA Vrana","year":"2024","unstructured":"Vrana, J. A. et al. A reliable clinical test for detection of membranous nephropathy antigens using laser microdissection and mass spectrometry. Kidney Int. 106, 907\u2013912 (2024).","journal-title":"Kidney Int."},{"key":"980_CR27","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1021\/ac0341261","volume":"75","author":"A Nesvizhskii","year":"2003","unstructured":"Nesvizhskii, A., Keller, A., Kolker, E. & Aebersold, R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75, 4646\u20134658 (2003).","journal-title":"Anal. Chem."},{"key":"980_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae305","volume":"17","author":"S Sethi","year":"2024","unstructured":"Sethi, S. & Fervenza, F. C. Why laser microdissection and mass spectrometry is the method of choice for detection of membranous nephropathy antigens. Clin. Kidney J. 17, sfae305 (2024).","journal-title":"Clin. Kidney J."},{"key":"980_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3181\/00379727-100-24736","volume":"100","author":"W Heymann","year":"1959","unstructured":"Heymann, W., Hackel, D. B., Harwood, S., Wilson, S. G. & Hunter, J. L. Production of nephrotic syndrome in rats by Freund\u2019s adjuvants and rat kidney suspensions. Proc. Soc. Exp. Biol. Med. 100, 660\u2013664 (1959).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"980_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1681\/ASN.V6135","volume":"6","author":"MG Farquhar","year":"1995","unstructured":"Farquhar, M. G., Saito, A., Kerjaschki, D. & Orlando, R. A. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J. Am. Soc. Nephrol. 6, 35\u201347 (1995).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR31","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1073\/pnas.94.6.2368","volume":"94","author":"RA Orlando","year":"1997","unstructured":"Orlando, R. A. et al. Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions. Proc. Natl Acad. Sci. USA 94, 2368\u20132373 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"980_CR32","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1073\/pnas.79.18.5557","volume":"79","author":"D Kerjaschki","year":"1982","unstructured":"Kerjaschki, D. & Farquhar, M. G. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc. Natl Acad. Sci. USA 79, 5557\u20135561 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"980_CR33","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa012895","volume":"346","author":"H Debiec","year":"2002","unstructured":"Debiec, H. et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 346, 2053\u20132060 (2002).","journal-title":"N. Engl. J. Med."},{"key":"980_CR34","doi-asserted-by":"publisher","first-page":"8963","DOI":"10.1074\/jbc.270.15.8963","volume":"270","author":"P Ancian","year":"1995","unstructured":"Ancian, P., Lambeau, G., Matt\u00e9i, M. G. & Lazdunski, M. The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J. Biol. Chem. 270, 8963\u20138970 (1995).","journal-title":"J. Biol. Chem."},{"key":"980_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.032","author":"L Zand","year":"2025","unstructured":"Zand, L. et al. Phospholipase A2receptor-positive membranous nephropathy detected by laser microdissection and mass spectrometry in patients negative by immunofluorescence for phospholipase A2receptor on kidney biopsy. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2025.04.032 (2025).","journal-title":"Kidney Int."},{"key":"980_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/j.ajkd.2020.10.009","volume":"77","author":"L Alsharhan","year":"2021","unstructured":"Alsharhan, L. & Beck, L. H. Jr Membranous nephropathy: core curriculum 2021. Am. J. Kidney Dis. 77, 440\u2013453 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"980_CR37","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/CJN.07210810","volume":"6","author":"JM Hofstra","year":"2011","unstructured":"Hofstra, J. M. et al. Receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1286\u20131291 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"980_CR38","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","volume":"22","author":"W Qin","year":"2011","unstructured":"Qin, W. et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1137\u20131143 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR39","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.kint.2015.11.032","volume":"89","author":"M-J Guerry","year":"2016","unstructured":"Guerry, M.-J., Vanhille, P., Ronco, P. & Debiec, H. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy. Kidney Int. 89, 1399 (2016).","journal-title":"Kidney Int."},{"key":"980_CR40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cca.2013.03.015","volume":"421","author":"C D\u00e4hnrich","year":"2013","unstructured":"D\u00e4hnrich, C. et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin. Chim. Acta 421, 213\u2013218 (2013).","journal-title":"Clin. Chim. Acta"},{"key":"980_CR41","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","volume":"22","author":"LH Beck","year":"2011","unstructured":"Beck, L. H. et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543\u20131550 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/ndt\/gfab356","volume":"38","author":"P Ronco","year":"2023","unstructured":"Ronco, P., Plaisier, E. & Debiec, H. The role of PLA2R antibody monitoring: what we know and what we do not know. Nephrol. Dial. Transpl. 38, 826\u2013833 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"980_CR43","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/ajt.13133","volume":"15","author":"A Kattah","year":"2015","unstructured":"Kattah, A. et al. Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy. Am. J. Transpl. 15, 1349\u20131359 (2015).","journal-title":"Am. J. Transpl."},{"key":"980_CR44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMc1003066","volume":"363","author":"R Stahl","year":"2010","unstructured":"Stahl, R., Hoxha, E. & Fechner, K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N. Engl. J. Med. 363, 496\u2013498 (2010).","journal-title":"N. Engl. J. Med."},{"key":"980_CR45","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1111\/j.1600-6143.2011.03643.x","volume":"11","author":"H Debiec","year":"2011","unstructured":"Debiec, H. et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and\u2002de novo\u2002membranous nephropathy. Am. J. Transpl. 11, 2144\u20132152 (2011).","journal-title":"Am. J. Transpl."},{"key":"980_CR46","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","volume":"95","author":"SA Bobart","year":"2019","unstructured":"Bobart, S. A. et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 95, 429\u2013438 (2019).","journal-title":"Kidney Int."},{"key":"980_CR47","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2215\/CJN.05480421","volume":"16","author":"SA Bobart","year":"2021","unstructured":"Bobart, S. A. et al. Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study. Clin. J. Am. Soc. Nephrol. 16, 1833\u20131839 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"980_CR48","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin, B. H. et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 100, 753\u2013779 (2021).","journal-title":"Kidney Int."},{"key":"980_CR49","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2215\/CJN.0000000671","volume":"20","author":"J Zee","year":"2025","unstructured":"Zee, J. et al. Non-invasive diagnostic strategies for membranous nephropathy in the NEPTUNE study. Clin. J. Am. Soc. Nephrol. 20, 697\u2013705 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"980_CR50","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.kint.2019.10.022","volume":"97","author":"C Meyer-Schwesinger","year":"2020","unstructured":"Meyer-Schwesinger, C. et al. A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients. Kidney Int. 97, 913\u2013919 (2020).","journal-title":"Kidney Int."},{"key":"980_CR51","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.kint.2023.07.024","volume":"104","author":"NM Tomas","year":"2023","unstructured":"Tomas, N. M. et al. Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy. Kidney Int. 104, 916\u2013928 (2023).","journal-title":"Kidney Int."},{"key":"980_CR52","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.kint.2022.09.008","volume":"103","author":"NM Tomas","year":"2023","unstructured":"Tomas, N. M. et al. Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice. Kidney Int. 103, 297\u2013303 (2023).","journal-title":"Kidney Int."},{"key":"980_CR53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1681\/ASN.0000000000000068","volume":"34","author":"L Reinhard","year":"2023","unstructured":"Reinhard, L. et al. Pathogenicity of human anti-PLA2R1 antibodies in minipigs: a pilot study. J. Am. Soc. Nephrol. 34, 369\u2013373 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR54","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1681\/ASN.2018090941","volume":"30","author":"J Herwig","year":"2019","unstructured":"Herwig, J. et al. Thrombospondin type 1 domain-containing 7A localizes to the slit diaphragm and stabilizes membrane dynamics of fully differentiated podocytes. J. Am. Soc. Nephrol. 30, 824\u2013839 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR55","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1681\/ASN.2017070805","volume":"29","author":"L Seifert","year":"2018","unstructured":"Seifert, L. et al. The most N-terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-associated membranous nephropathy. J. Am. Soc. Nephrol. 29, 1536\u20131548 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR56","doi-asserted-by":"publisher","first-page":"1430451","DOI":"10.3389\/fphar.2024.1430451","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. THSD7A-associated membranous nephropathy involves both complement-mediated and autonomous podocyte injury. Front. Pharmacol. 15, 1430451 (2024).","journal-title":"Front. Pharmacol."},{"key":"980_CR57","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMc1511702","volume":"374","author":"E Hoxha","year":"2016","unstructured":"Hoxha, E. et al. A mechanism for cancer-associated membranous nephropathy. N. Engl. J. Med. 374, 1995\u20131996 (2016).","journal-title":"N. Engl. J. Med."},{"key":"980_CR58","doi-asserted-by":"publisher","first-page":"217","DOI":"10.34067\/KID.0005112022","volume":"4","author":"PD Burbelo","year":"2023","unstructured":"Burbelo, P. D. et al. Prediagnostic appearance of thrombospondin type-1 domain 7A autoantibodies in membranous nephropathy. Kidney360 4, 217\u2013225 (2023).","journal-title":"Kidney360"},{"key":"980_CR59","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.kint.2018.10.024","volume":"95","author":"C Zaghrini","year":"2019","unstructured":"Zaghrini, C. et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. 95, 666\u2013679 (2019).","journal-title":"Kidney Int."},{"key":"980_CR60","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.yexcr.2012.02.031","volume":"318","author":"JH Miner","year":"2012","unstructured":"Miner, J. H. The glomerular basement membrane. Exp. Cell Res. 318, 973\u2013978 (2012).","journal-title":"Exp. Cell Res."},{"key":"980_CR61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.trsl.2012.03.004","volume":"160","author":"YM Chen","year":"2012","unstructured":"Chen, Y. M. & Miner, J. H. Glomerular basement membrane and related glomerular disease. Transl. Res. 160, 291\u2013297 (2012).","journal-title":"Transl. Res."},{"key":"980_CR62","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00467-011-1785-1","volume":"26","author":"JH Miner","year":"2011","unstructured":"Miner, J. H. Glomerular basement membrane composition and the filtration barrier. Pediatr. Nephrol. 26, 1413\u20131417 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"980_CR63","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1523-1755.2000.00858.x","volume":"57","author":"CJI Raats","year":"2000","unstructured":"Raats, C. J. I., Van Den Born, J. & Berden, J. H. M. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int. 57, 385\u2013400 (2000).","journal-title":"Kidney Int."},{"key":"980_CR64","doi-asserted-by":"publisher","first-page":"F1123","DOI":"10.1152\/ajprenal.00603.2015","volume":"310","author":"T Sugar","year":"2016","unstructured":"Sugar, T. et al. N-sulfation of heparan sulfate is critical for syndecan-4-mediated podocyte cell-matrix interactions. Am. J. Physiol. Renal Physiol. 310, F1123\u2013F1135 (2016).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"980_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1017\/S1431927611012682","volume":"18","author":"KJ McCarthy","year":"2012","unstructured":"McCarthy, K. J. & Wassenhove-McCarthy, D. J. The glomerular basement membrane as a model system to study the bioactivity of heparan sulfate glycosaminoglycans. Microsc. Microanal. 18, 3\u201321 (2012).","journal-title":"Microsc. Microanal."},{"key":"980_CR66","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/ki.2013.281","volume":"85","author":"T Sugar","year":"2014","unstructured":"Sugar, T. et al. Podocyte-specific deletion of NDST1, a key enzyme in the sulfation of heparan sulfate glycosaminoglycans, leads to abnormalities in podocyte organization in vivo. Kidney Int. 85, 307\u2013318 (2014).","journal-title":"Kidney Int."},{"key":"980_CR67","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ki.2010.136","volume":"78","author":"S Chen","year":"2010","unstructured":"Chen, S. et al. Podocytes require the engagement of cell surface heparan sulfate proteoglycans for adhesion to extracellular matrices. Kidney Int. 78, 1088\u20131099 (2010).","journal-title":"Kidney Int."},{"key":"980_CR68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.matbio.2013.10.001","volume":"35","author":"M Busse-Wicher","year":"2014","unstructured":"Busse-Wicher, M., Wicher, K. B. & Kusche-Gullberg, M. The exostosin family: proteins with many functions. Matrix Biol. 35, 25\u201333 (2014).","journal-title":"Matrix Biol."},{"key":"980_CR69","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/ng1095-137","volume":"11","author":"J Ahn","year":"1995","unstructured":"Ahn, J. et al. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat. Genet. 11, 137\u2013143 (1995).","journal-title":"Nat. Genet."},{"key":"980_CR70","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1172\/JCI13737","volume":"108","author":"G Duncan","year":"2001","unstructured":"Duncan, G., McCormick, C. & Tufaro, F. The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins. J. Clin. Invest. 108, 511\u2013516 (2001).","journal-title":"J. Clin. Invest."},{"key":"980_CR71","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1073\/pnas.97.2.668","volume":"97","author":"C McCormick","year":"2000","unstructured":"McCormick, C., Duncan, G., Goutsos, K. T. & Tufaro, F. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc. Natl Acad. Sci. USA 97, 668\u2013673 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"980_CR72","doi-asserted-by":"publisher","first-page":"32802","DOI":"10.1074\/jbc.M703560200","volume":"282","author":"M Busse","year":"2007","unstructured":"Busse, M. et al. Contribution of EXT1, EXT2, and EXTL3 to heparan sulfate chain elongation. J. Biol. Chem. 282, 32802\u201332810 (2007).","journal-title":"J. Biol. Chem."},{"key":"980_CR73","doi-asserted-by":"publisher","first-page":"41333","DOI":"10.1074\/jbc.M308314200","volume":"278","author":"M Busse","year":"2003","unstructured":"Busse, M. & Kusche-Gullberg, M. In vitro polymerization of heparan sulfate backbone by the EXT proteins. J. Biol. Chem. 278, 41333\u201341337 (2003).","journal-title":"J. Biol. Chem."},{"key":"980_CR74","doi-asserted-by":"publisher","first-page":"17615","DOI":"10.1016\/S0021-9258(19)84610-0","volume":"264","author":"JC Paulson","year":"1989","unstructured":"Paulson, J. C. & Colley, K. J. Glycosyltransferases. Structure, localization, and control of cell type-specific glycosylation. J. Biol. Chem. 264, 17615\u201317618 (1989).","journal-title":"J. Biol. Chem."},{"key":"980_CR75","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1681\/ASN.2020081181","volume":"32","author":"A Ravindran","year":"2021","unstructured":"Ravindran, A. et al. In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes. J. Am. Soc. Nephrol. 32, 695\u2013706 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR76","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.ekir.2021.04.025","volume":"6","author":"M Sa\u00efdi","year":"2021","unstructured":"Sa\u00efdi, M. et al. The exostosin immunohistochemical status differentiates lupus membranous nephropathy subsets with different outcomes. Kidney Int. Rep. 6, 1977\u20131980 (2021).","journal-title":"Kidney Int. Rep."},{"key":"980_CR77","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.ekir.2024.01.008","volume":"9","author":"X Xia","year":"2024","unstructured":"Xia, X. et al. Glomerular exostosin-positivity is associated with disease activity and outcomes in patients with membranous lupus nephritis. Kidney Int. Rep. 9, 1040\u20131046 (2024).","journal-title":"Kidney Int. Rep."},{"key":"980_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001051","volume":"10","author":"T Ye","year":"2023","unstructured":"Ye, T. et al. Clinical significance of exostosin 1 in confirmed and suspected lupus membranous nephropathy. Lupus Sci. Med. 10, e001051, (2023).","journal-title":"Lupus Sci. Med."},{"key":"980_CR79","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s10067-024-07043-x","volume":"43","author":"MF Zavala-Miranda","year":"2024","unstructured":"Zavala-Miranda, M. F. et al. Exostosin-1\/exostosin-2 expression and favorable kidney outcomes in lupus nephritis: a retrospective cohort study. Clin. Rheumatol. 43, 2533\u20132540 (2024).","journal-title":"Clin. Rheumatol."},{"key":"980_CR80","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.xkme.2021.03.013","volume":"3","author":"T Iwakura","year":"2021","unstructured":"Iwakura, T. et al. Primary membranous nephropathy with enhanced staining of exostosin 1\/exostosin 2 in the glomeruli: a report of 2 cases. Kidney Med. 3, 669\u2013673 (2021).","journal-title":"Kidney Med."},{"key":"980_CR81","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1016\/j.ekir.2024.09.009","volume":"9","author":"EP Lafaut","year":"2024","unstructured":"Lafaut, E. P., Fragoso, P., Haas, M. & Sethi, S. De novo exostosin-associated membranous nephropathy in kidney transplant. Kidney Int. Rep. 9, 3349\u20133350 (2024).","journal-title":"Kidney Int. Rep."},{"key":"980_CR82","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/aja.1002030209","volume":"203","author":"S Matshuhashi","year":"1995","unstructured":"Matshuhashi, S. et al. New gene, nel, encoding a Mr 93 K protein with EGF-like repeats is strongly expressed in neural tissues of early stage chick embryos. Dev. Dyn. 203, 212\u2013222 (1995).","journal-title":"Dev. Dyn."},{"key":"980_CR83","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1177\/0022034510376401","volume":"89","author":"X Zhang","year":"2010","unstructured":"Zhang, X., Zara, J., Siu, R. K., Ting, K. & Soo, C. The role of NELL-1, a growth factor associated with craniosynostosis, in promoting bone regeneration. J. Dent. Res. 89, 865\u2013878 (2010).","journal-title":"J. Dent. Res."},{"key":"980_CR84","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1006\/bbrc.1999.1638","volume":"265","author":"S Kuroda","year":"1999","unstructured":"Kuroda, S. et al. Biochemical characterization and expression analysis of neural thrombospondin-1-like proteins NELL1 and NELL2. Biochem. Biophys. Res. Commun. 265, 79\u201386 (1999).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"980_CR85","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1006\/geno.1996.0628","volume":"38","author":"TK Watanabe","year":"1996","unstructured":"Watanabe, T. K. et al. Cloning and characterization of two novel human cDNAs (NELL1 and NELL2) encoding proteins with six EGF-like repeats. Genomics 38, 273\u2013276 (1996).","journal-title":"Genomics"},{"key":"980_CR86","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.kint.2020.06.014","volume":"99","author":"S Kudose","year":"2021","unstructured":"Kudose, S. et al. The clinicopathologic spectrum of segmental membranous glomerulopathy. Kidney Int. 99, 247\u2013255 (2021).","journal-title":"Kidney Int."},{"key":"980_CR87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.kint.2019.10.009","volume":"97","author":"SB Ahmad","year":"2020","unstructured":"Ahmad, S. B. & Appel, G. B. Antigens, antibodies, and membranous nephropathy: a decade of progress. Kidney Int. 97, 29\u201331 (2020).","journal-title":"Kidney Int."},{"key":"980_CR88","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.11860720","volume":"16","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in Chinese patients. Clin. J. Am. Soc. Nephrol. 16, 727\u2013735 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"980_CR89","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ckj\/sfac237","volume":"16","author":"S Sethi","year":"2023","unstructured":"Sethi, S. The many faces of NELL1 MN. Clin. Kidney J. 16, 442\u2013446 (2023).","journal-title":"Clin. Kidney J."},{"key":"980_CR90","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","volume":"99","author":"TN Caza","year":"2021","unstructured":"Caza, T. N. et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int. 99, 967\u2013976 (2021).","journal-title":"Kidney Int."},{"key":"980_CR91","volume":"15","author":"A Fujii","year":"2023","unstructured":"Fujii, A., Hayashi, N., Fujita, H., Yokoyama, H. & Furuichi, K. A case of spontaneous remission of membranous nephropathy after the removal of nerve epidermal growth factor-like 1 positive sigmoid colon carcinoma. Cureus 15, e49892 (2023).","journal-title":"Cureus"},{"key":"980_CR92","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/ckj\/sfac261","volume":"16","author":"S Zhou","year":"2023","unstructured":"Zhou, S. et al. Backtracking cryptic recurrence of esophageal cancer from membranous nephropathy: the detection of glomerular NELL-1 and IgG4. Clin. Kidney J. 16, 756\u2013759 (2023).","journal-title":"Clin. Kidney J."},{"key":"980_CR93","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.ekir.2024.02.1401","volume":"9","author":"RS Avasare","year":"2024","unstructured":"Avasare, R. S. et al. Characteristics and outcomes of NELL1 membranous nephropathy in lipoic acid users and nonusers. Kidney Int. Rep. 9, 1379\u20131386 (2024).","journal-title":"Kidney Int. Rep."},{"key":"980_CR94","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.kint.2021.10.010","volume":"100","author":"RI Spain","year":"2021","unstructured":"Spain, R. I. et al. Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy. Kidney Int. 100, 1208\u20131213 (2021).","journal-title":"Kidney Int."},{"key":"980_CR95","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.kint.2024.03.025","volume":"105","author":"R Narayanan","year":"2024","unstructured":"Narayanan, R., Sivadas, S. & Kurien, A. A. NELL-1-associated membranous nephropathy linked to skin fairness cream use: insights from an Indian case series. Kidney Int. 105, 1316\u20131319 (2024).","journal-title":"Kidney Int."},{"key":"980_CR96","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.kint.2022.09.001","volume":"102","author":"AA Kurien","year":"2022","unstructured":"Kurien, A. A., Prema Ks, J., Walker, P. & Caza, T. Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy. Kidney Int. 102, 1424\u20131426 (2022).","journal-title":"Kidney Int."},{"key":"980_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100827","volume":"6","author":"PK Devaraju","year":"2024","unstructured":"Devaraju, P. K. et al. Complementary and alternative medicine use and glomerular disease: a contemporary case series. Kidney Med. 6, 100827 (2024).","journal-title":"Kidney Med."},{"key":"980_CR98","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.ekir.2024.02.1405","volume":"9","author":"S Narayanasami","year":"2024","unstructured":"Narayanasami, S. et al. Clinical characteristics and outcomes of neural epidermal growth factor-like 1 protein-associated membranous nephropathy. Kidney Int. Rep. 9, 1513\u20131516 (2024).","journal-title":"Kidney Int. Rep."},{"key":"980_CR99","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.ekir.2023.05.023","volume":"8","author":"D Santoriello","year":"2023","unstructured":"Santoriello, D., Ramaswamy, R., Kudose, S. & Markowitz, G. S. Segmental NELL-1 membranous nephropathy complicating tiopronin therapy. Kidney Int. Rep. 8, 1683\u20131686 (2023).","journal-title":"Kidney Int. Rep."},{"key":"980_CR100","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00428-024-03921-6","volume":"486","author":"T Hyodo","year":"2024","unstructured":"Hyodo, T. et al. Clinicopathological characteristics of neural epidermal growth factor-like 1 protein-associated membranous glomerulonephritis. Virchows Arch. 486, 991\u20131000 (2024).","journal-title":"Virchows Arch."},{"key":"980_CR101","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ekir.2024.10.044","volume":"10","author":"AB Dirim","year":"2025","unstructured":"Dirim, A. B. et al. NELL-1-associated membranous nephropathy induced by long-term penicillamine treatment in a patient with Wilson\u2019s disease. Kidney Int. Rep. 10, 614\u2013615 (2025).","journal-title":"Kidney Int. Rep."},{"key":"980_CR102","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/ki.1996.240","volume":"49","author":"JB Pritchard","year":"1996","unstructured":"Pritchard, J. B. & Miller, D. S. Renal secretion of organic anions and cations. Kidney Int. 49, 1649\u20131654 (1996).","journal-title":"Kidney Int."},{"key":"980_CR103","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1111\/ajt.16610","volume":"21","author":"J M\u00fcnch","year":"2021","unstructured":"M\u00fcnch, J. et al. Posttransplant nephrotic syndrome resulting from NELL1-positive membranous nephropathy. Am. J. Transpl. 21, 3175\u20133179 (2021).","journal-title":"Am. J. Transpl."},{"key":"980_CR104","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ajt.2024.11.026","volume":"25","author":"A Kenan","year":"2024","unstructured":"Kenan, A. et al. Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in renal allografts: a series of 6 patients. Am. J. Transpl. 25, 860\u2013866 (2024).","journal-title":"Am. J. Transpl."},{"key":"980_CR105","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1016\/j.ekir.2021.04.033","volume":"6","author":"S Kudose","year":"2021","unstructured":"Kudose, S. et al. NELL1-associated membranous glomerulopathy after hematopoietic stem cell transplantation. Kidney Int. Rep. 6, 1992\u20131995 (2021).","journal-title":"Kidney Int. Rep."},{"key":"980_CR106","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/sj.ki.5000313","volume":"69","author":"F Guan","year":"2006","unstructured":"Guan, F., Villegas, G., Teichman, J., Mundel, P. & Tufro, A. Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival. Kidney Int. 69, 1564\u20131569 (2006).","journal-title":"Kidney Int."},{"key":"980_CR107","doi-asserted-by":"crossref","unstructured":"Alto, L. T. & Terman, J. R. in Semaphorin Signaling: Methods and Protocols (ed. Terman, J. R.) 1\u201325 (Springer, 2017).","DOI":"10.1007\/978-1-4939-6448-2_1"},{"key":"980_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2006-7-3-211","volume":"7","author":"U Yazdani","year":"2006","unstructured":"Yazdani, U. & Terman, J. R. The semaphorins. Genome Biol. 7, 211 (2006).","journal-title":"Genome Biol."},{"key":"980_CR109","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/sj.ki.5002726","volume":"73","author":"R Tapia","year":"2008","unstructured":"Tapia, R. et al. Semaphorin3\u0251 disrupts podocyte foot processes causing acute proteinuria. Kidney Int. 73, 733\u2013740 (2008).","journal-title":"Kidney Int."},{"key":"980_CR110","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1007\/s00467-022-05503-7","volume":"37","author":"P Miller","year":"2022","unstructured":"Miller, P. et al. Clinicopathologic features of non-lupus membranous nephropathy in a pediatric population. Pediatr. Nephrol. 37, 3127\u20133137 (2022).","journal-title":"Pediatr. Nephrol."},{"key":"980_CR111","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00467-023-06085-8","volume":"39","author":"E Conversano","year":"2024","unstructured":"Conversano, E. et al. A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance. Pediatr. Nephrol. 39, 305\u2013308 (2024).","journal-title":"Pediatr. Nephrol."},{"key":"980_CR112","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13730-022-00763-6","volume":"12","author":"Y Tanaka","year":"2023","unstructured":"Tanaka, Y., Yamamoto, M., Nozu, K. & Hara, S. An 8-month-old boy with infantile nephrotic syndrome caused by semaphorin 3B-associated membranous nephropathy. CEN Case Rep. 12, 281\u2013286 (2023).","journal-title":"CEN Case Rep."},{"key":"980_CR113","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1681\/ASN.2021101323","volume":"33","author":"M Fila","year":"2022","unstructured":"Fila, M. et al. Recurrence of anti-semaphorin 3B-mediated membranous nephropathy after kidney transplantation. J. Am. Soc. Nephrol. 33, 503\u2013509 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR114","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tins.2017.03.003","volume":"40","author":"V Sytnyk","year":"2017","unstructured":"Sytnyk, V., Leshchyns\u2019ka, I. & Schachner, M. Neural cell adhesion molecules of the immunoglobulin superfamily regulate synapse formation, maintenance, and function. Trends Neurosci. 40, 295\u2013308 (2017).","journal-title":"Trends Neurosci."},{"key":"980_CR115","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/ndt\/gfac058","volume":"38","author":"PP Miller","year":"2023","unstructured":"Miller, P. P., Caza, T., Larsen, C. P. & Charu, V. EXT1 and NCAM1-associated membranous lupus nephritis in a cohort of patients undergoing repeat kidney biopsies. Nephrol. Dial. Transpl. 38, 396\u2013404 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"980_CR116","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/ndt\/gfae148","volume":"40","author":"X Xia","year":"2024","unstructured":"Xia, X. et al. Clinicopathological phenotype and outcomes of NCAM-1+ membranous lupus nephritis. Nephrol. Dial. Transpl. 40, 193\u2013205 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"980_CR117","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.tcb.2012.03.004","volume":"22","author":"J Brasch","year":"2012","unstructured":"Brasch, J., Harrison, O. J., Honig, B. & Shapiro, L. Thinking outside the cell: how cadherins drive adhesion. Trends Cell Biol. 22, 299\u2013310 (2012).","journal-title":"Trends Cell Biol."},{"key":"980_CR118","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1101\/gad.1486806","volume":"20","author":"JM Halbleib","year":"2006","unstructured":"Halbleib, J. M. & Nelson, W. J. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 20, 3199\u20133214 (2006).","journal-title":"Genes Dev."},{"key":"980_CR119","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ceb.2007.09.006","volume":"19","author":"H Morishita","year":"2007","unstructured":"Morishita, H. & Yagi, T. Protocadherin family: diversity, structure, and function. Curr. Opin. Cell Biol. 19, 584\u2013592 (2007).","journal-title":"Curr. Opin. Cell Biol."},{"key":"980_CR120","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13730-023-00842-2","volume":"13","author":"N Fu","year":"2024","unstructured":"Fu, N., Yuan, S., Yang, G., Li, H. & Wang, T. Concurrent glomerular PCDH7 deposits in PLA2R-associated membranous nephropathy. CEN Case Rep. 13, 297\u2013301 (2024).","journal-title":"CEN Case Rep."},{"key":"980_CR121","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.kint.2024.10.012","volume":"107","author":"M Machalitza","year":"2025","unstructured":"Machalitza, M. et al. PCDH7-antibodies and PCDH7 immune deposits are mostly found in patients with PLA2R1- or NELL1-associated membranous nephropathy. Kidney Int. 107, 188\u2013191 (2025).","journal-title":"Kidney Int."},{"key":"980_CR122","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/med.21286","volume":"34","author":"E Sadeqzadeh","year":"2014","unstructured":"Sadeqzadeh, E., de Bock, C. E. & Thorne, R. F. Sleeping giants: emerging roles for the fat cadherins in health and disease. Med. Res. Rev. 34, 190\u2013221 (2014).","journal-title":"Med. Res. Rev."},{"key":"980_CR123","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1046\/j.1523-1755.2001.0590031003.x","volume":"59","author":"T Inoue","year":"2001","unstructured":"Inoue, T. et al. FAT is a component of glomerular slit diaphragms. Kidney Int. 59, 1003\u20131012 (2001).","journal-title":"Kidney Int."},{"key":"980_CR124","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1523-1755.2005.00432.x","volume":"68","author":"E Yaoita","year":"2005","unstructured":"Yaoita, E. et al. Role of Fat1 in cell-cell contact formation of podocytes in puromycin aminonucleoside nephrosis and neonatal kidney. Kidney Int. 68, 542\u2013551 (2005).","journal-title":"Kidney Int."},{"key":"980_CR125","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/PAP.0000000000000034","volume":"21","author":"ML Troxell","year":"2014","unstructured":"Troxell, M. L., Higgins, J. P. & Kambham, N. Renal pathology associated with hematopoietic stem cell transplantation. Adv. Anat. Pathol. 21, 330\u2013340 (2014).","journal-title":"Adv. Anat. Pathol."},{"key":"980_CR126","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2215\/CJN.01700407","volume":"2","author":"A Chang","year":"2007","unstructured":"Chang, A. et al. Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature. Clin. J. Am. Soc. Nephrol. 2, 1014\u20131023 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"980_CR127","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40620-023-01786-7","volume":"37","author":"N Mongera","year":"2024","unstructured":"Mongera, N., Passler, W., Sethi, S., Kozakowski, N. & Tabb\u00ec, M. G. A case of protocadherin FAT1-positive membranous nephropathy secondary to hematopoietic stem-cell transplantation. J. Nephrol. 37, 1153\u20131156 (2024).","journal-title":"J. Nephrol."},{"key":"980_CR128","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12882-024-03675-y","volume":"25","author":"I Bosni\u0107 Kova\u010di\u0107","year":"2024","unstructured":"Bosni\u0107 Kova\u010di\u0107, I. et al. Specific antigen-based stratification of membranous nephropathy in patients after haematopoietic stem cell allotransplantation \u2014 a case series and literature review. BMC Nephrol. 25, 254 (2024).","journal-title":"BMC Nephrol."},{"key":"980_CR129","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ekir.2024.10.012","volume":"10","author":"LF Al-Rabadi","year":"2025","unstructured":"Al-Rabadi, L. F. et al. De novo membranous nephropathy in renal allografts is associated with protocadherin FAT1. Kidney Int. Rep. 10, 247\u2013251 (2025).","journal-title":"Kidney Int. Rep."},{"key":"980_CR130","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1042\/bj3210587","volume":"321","author":"RE Mains","year":"1997","unstructured":"Mains, R. E. et al. PACE4: a subtilisin-like endoprotease with unique properties. Biochem. J. 321, 587\u2013593 (1997).","journal-title":"Biochem. J."},{"key":"980_CR131","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/oxfordjournals.jbchem.a021772","volume":"122","author":"A Tsuji","year":"1997","unstructured":"Tsuji, A. et al. Genomic organization and alternative splicing of human PACE4 (SPC4), kexin-like processing endoprotease1. J. Biochem. 122, 438\u2013452 (1997).","journal-title":"J. Biochem."},{"key":"980_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-11-137","volume":"11","author":"XL Kuang","year":"2010","unstructured":"Kuang, X. L. et al. Spatio-temporal expression of a novel neuron-derived neurotrophic factor (NDNF) in mouse brains during development. BMC Neurosci. 11, 137 (2010).","journal-title":"BMC Neurosci."},{"key":"980_CR133","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(16)32411-4","volume":"389","author":"EW Hook","year":"2017","unstructured":"Hook, E. W. Syphilis. Lancet 389, 1550\u20131557 (2017).","journal-title":"Lancet"},{"key":"980_CR134","doi-asserted-by":"publisher","first-page":"o2355","DOI":"10.1136\/bmj.o2355","volume":"378","author":"O Dyer","year":"2022","unstructured":"Dyer, O. Syphilis and gonorrhoea cases soar in US. BMJ 378, o2355 (2022).","journal-title":"BMJ"},{"key":"980_CR135","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/imj.15407","volume":"51","author":"R Shettigar","year":"2021","unstructured":"Shettigar, R. et al. Renal manifestations of syphilis. Intern. Med. J. 51, 1160\u20131167 (2021).","journal-title":"Intern. Med. J."},{"key":"980_CR136","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.ekir.2025.03.052","volume":"10","author":"D Fang","year":"2025","unstructured":"Fang, D., Storey, A. J., Hassen, S. I., Larsen, C. P. & Caza, T. N. Spectrum of kidney pathology in patients with syphilis. Kidney Int. Rep. 10, 2015\u20132023 (2025).","journal-title":"Kidney Int. Rep."},{"key":"980_CR137","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ekir.2023.11.021","volume":"9","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. Target antigens of membranous nephropathy with syphilis infection. Kidney Int. Rep. 9, 401\u2013409 (2024).","journal-title":"Kidney Int. Rep."},{"key":"980_CR138","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.ajkd.2024.02.007","volume":"84","author":"D Honda","year":"2024","unstructured":"Honda, D. et al. Anti-neuron-derived neurotrophic factor antibodies in secondary membranous nephropathy caused by syphilis: a case report. Am. J. Kidney Dis. 84, 250\u2013254 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"980_CR139","doi-asserted-by":"crossref","unstructured":"Mohebiany, A. N., Harroch, S. & Bouyain, S. in Cell Adhesion Molecules: Implications in Neurological Diseases (eds Berezin, V. & Walmod, P. S.) 165\u2013194 (Springer, 2014).","DOI":"10.1007\/978-1-4614-8090-7_8"},{"key":"980_CR140","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.kint.2021.08.029","volume":"100","author":"E Plaisier","year":"2021","unstructured":"Plaisier, E., Not, A., Buob, D., Ronco, P. & Debiec, H. Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab. Kidney Int. 100, 1342\u20131344 (2021).","journal-title":"Kidney Int."},{"key":"980_CR141","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281156","volume":"18","author":"J Fehmi","year":"2023","unstructured":"Fehmi, J. et al. Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis. PLoS ONE 18, e0281156 (2023).","journal-title":"PLoS ONE"},{"key":"980_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759187","volume":"12","author":"Q Xu","year":"2021","unstructured":"Xu, Q. et al. Characteristics of anti-contactin1 antibody-associated autoimmune nodopathies with concomitant membranous nephropathy. Front. Immunol. 12, 759187 (2021).","journal-title":"Front. Immunol."},{"key":"980_CR143","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1053\/j.ajkd.2021.08.025","volume":"80","author":"D Santoro","year":"2022","unstructured":"Santoro, D. et al. Contactin 1, a potential new antigen target in membranous nephropathy: a case report. Am. J. Kidney Dis. 80, 289\u2013294 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"980_CR144","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1007\/s00415-020-10041-z","volume":"267","author":"E Delmont","year":"2020","unstructured":"Delmont, E. et al. Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. J. Neurol. 267, 3664\u20133672 (2020).","journal-title":"J. Neurol."},{"key":"980_CR145","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/CND.0000000000000395","volume":"23","author":"G Remiche","year":"2022","unstructured":"Remiche, G. et al. Rituximab responsive relapsing-remitting IgG4 anticontactin 1 chronic inflammatory demyelinating polyradiculoneuropathy associated with membranous nephropathy: a case description and brief review. J. Clin. Neuromuscul. Dis. 23, 219\u2013226 (2022).","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"980_CR146","doi-asserted-by":"publisher","first-page":"8244","DOI":"10.1074\/jbc.M117.775031","volume":"292","author":"I Grishkovskaya","year":"2017","unstructured":"Grishkovskaya, I. et al. Structure of human promyeloperoxidase (proMPO) and the role of the propeptide in processing and maturation. J. Biol. Chem. 292, 8244\u20138261 (2017).","journal-title":"J. Biol. Chem."},{"key":"980_CR147","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.ekir.2019.07.021","volume":"4","author":"A Nikolopoulou","year":"2019","unstructured":"Nikolopoulou, A. et al. Membranous glomerulonephritis with crescents. Kidney Int. Rep. 4, 1577\u20131584 (2019).","journal-title":"Kidney Int. Rep."},{"key":"980_CR148","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.humpath.2010.08.020","volume":"42","author":"K Hanamura","year":"2011","unstructured":"Hanamura, K. et al. Detection of myeloperoxidase in membranous nephropathy-like deposits in patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Hum. Pathol. 42, 649\u2013658 (2011).","journal-title":"Hum. Pathol."},{"key":"980_CR149","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2215\/CJN.04060808","volume":"4","author":"SH Nasr","year":"2009","unstructured":"Nasr, S. H. et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin. J. Am. Soc. Nephrol. 4, 299\u2013308 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"980_CR150","first-page":"461","volume":"2","author":"K Matsumoto","year":"2009","unstructured":"Matsumoto, K. et al. MPO-ANCA crescentic glomerulonephritis complicated by membranous nephropathy: MPO demonstrated in epimembranous deposits. NDT Plus 2, 461\u2013465 (2009).","journal-title":"NDT Plus"},{"key":"980_CR151","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ekir.2025.03.001","volume":"10","author":"R Gietzen","year":"2025","unstructured":"Gietzen, R., Caza, T. N., Best-Rocha, A. & Larsen, C. P. The utility of myeloperoxidase immunostaining to characterize immune deposits in patients with crescentic glomerulonephritis. Kidney Int. Rep. 10, 1460\u20131467 (2025).","journal-title":"Kidney Int. Rep."},{"key":"980_CR152","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.kint.2023.10.035","volume":"105","author":"AD Kistler","year":"2024","unstructured":"Kistler, A. D. & Salant, D. J. Complement activation and effector pathways in membranous nephropathy. Kidney Int. 105, 473\u2013483 (2024).","journal-title":"Kidney Int."},{"key":"980_CR153","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ekir.2020.01.018","volume":"5","author":"A Ravindran","year":"2020","unstructured":"Ravindran, A. et al. Proteomic analysis of complement proteins in membranous nephropathy. Kidney Int. Rep. 5, 618\u2013626 (2020).","journal-title":"Kidney Int. Rep."},{"key":"980_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36068-0","volume":"14","author":"L Seifert","year":"2023","unstructured":"Seifert, L. et al. The classical pathway triggers pathogenic complement activation in membranous nephropathy. Nat. Commun. 14, 473 (2023).","journal-title":"Nat. Commun."},{"key":"980_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-65","volume":"8","author":"T Stehl\u00e9","year":"2013","unstructured":"Stehl\u00e9, T. et al. Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study. Orphanet J. Rare Dis. 8, 65 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"980_CR156","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1053\/j.ajkd.2011.05.006","volume":"58","author":"FC Fervenza","year":"2011","unstructured":"Fervenza, F. C., Downer, G., Beck, L. H. Jr. & Sethi, S. IgG4-related tubulointerstitial nephritis with membranous nephropathy. Am. J. Kidney Dis. 58, 320\u2013324 (2011).","journal-title":"Am. J. Kidney Dis."},{"key":"980_CR157","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/ki.2012.382","volume":"83","author":"MP Alexander","year":"2013","unstructured":"Alexander, M. P. et al. Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int. 83, 455\u2013462 (2013).","journal-title":"Kidney Int."},{"key":"980_CR158","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.ekir.2023.03.019","volume":"8","author":"D Zubidat","year":"2023","unstructured":"Zubidat, D. et al. Heterogeneity of target antigens in sarcoidosis-associated membranous nephropathy. Kidney Int. Rep. 8, 1213\u20131219 (2023).","journal-title":"Kidney Int. Rep."},{"key":"980_CR159","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.kint.2025.01.029","volume":"107","author":"L Zand","year":"2025","unstructured":"Zand, L. & Sethi, S. The authors reply. Kidney Int. 107, 936\u2013937 (2025).","journal-title":"Kidney Int."},{"key":"980_CR160","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.kint.2024.12.022","volume":"107","author":"C Hanna","year":"2025","unstructured":"Hanna, C. et al. PCSK6-associated membranous nephropathy in an adolescent with Sj\u00f6gren disease. Kidney Int. 107, 940\u2013942 (2025).","journal-title":"Kidney Int."},{"key":"980_CR161","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2215\/CJN.01330209","volume":"4","author":"MA Hladunewich","year":"2009","unstructured":"Hladunewich, M. A., Troyanov, S., Calafati, J., Cattran, D. C. & for the Metropolitan Toronto Glomerulonephritis Registry. The natural history of the non-nephrotic membranous nephropathy patient. Clin. J. Am. Soc. Nephrol. 4, 1417\u20131422 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"980_CR162","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/ndt\/gfad225","volume":"39","author":"Y Radhakrishnan","year":"2024","unstructured":"Radhakrishnan, Y., Zand, L., Sethi, S. & Fervenza, F. C. Membranous nephropathy treatment standard. Nephrol. Dial. Transpl. 39, 403\u2013413 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"980_CR163","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/ckj\/sfad075","volume":"16","author":"L Zand","year":"2023","unstructured":"Zand, L. & Fervenza, F. C. Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy. Clin. Kidney J. 16, 1420\u20131425 (2023).","journal-title":"Clin. Kidney J."},{"key":"980_CR164","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/MNH.0000000000001039","volume":"34","author":"F Caravaca-Font\u00e1n","year":"2025","unstructured":"Caravaca-Font\u00e1n, F., Yandian, F. & Fervenza, F. C. Updated diagnostic and therapeutic management for membranous nephropathy. Curr. Opin. Nephrol. Hypertens. 34, 23\u201332 (2025).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"980_CR165","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ekir.2022.12.011","volume":"8","author":"JE Rojas-Rivera","year":"2023","unstructured":"Rojas-Rivera, J. E., Ortiz, A. & Fervenza, F. C. Novel treatments paradigms: membranous nephropathy. Kidney Int. Rep. 8, 419\u2013431 (2023).","journal-title":"Kidney Int. Rep."},{"key":"980_CR166","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza, F. C. et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 381, 36\u201346 (2019).","journal-title":"N. Engl. J. Med."},{"key":"980_CR167","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","volume":"99","author":"G Fern\u00e1ndez-Ju\u00e1rez","year":"2021","unstructured":"Fern\u00e1ndez-Ju\u00e1rez, G. et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 99, 986\u2013998 (2021).","journal-title":"Kidney Int."},{"key":"980_CR168","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari, F. et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO randomized trial. J. Am. Soc. Nephrol. 32, 972\u2013982 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR169","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ekir.2019.12.006","volume":"5","author":"N Hanset","year":"2020","unstructured":"Hanset, N. et al. Rituximab in patients with phospholipase A2 receptor-associated membranous nephropathy and severe CKD. Kidney Int. Rep. 5, 331\u2013338 (2020).","journal-title":"Kidney Int. Rep."},{"key":"980_CR170","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","volume":"76","author":"N Klomjit","year":"2020","unstructured":"Klomjit, N., Fervenza, F. C. & Zand, L. Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases. Am. J. Kidney Dis. 76, 883\u2013888 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"980_CR171","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04629248 (2025)."},{"key":"980_CR172","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS De Vriese","year":"2017","unstructured":"De Vriese, A. S., Glassock, R. J., Nath, K. A., Sethi, S. & Fervenza, F. C. A proposal for a serology-based approach to membranous nephropathy. J. Am. Soc. Nephrol. 28, 421\u2013430 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR173","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2215\/CJN.0000000000000237","volume":"18","author":"SJ Barbour","year":"2023","unstructured":"Barbour, S. J. et al. Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy. Clin. J. Am. Soc. Nephrol. 18, 1283\u20131293 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"980_CR174","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2215\/CJN.0000000000000086","volume":"18","author":"G Fern\u00e1ndez-Ju\u00e1rez","year":"2023","unstructured":"Fern\u00e1ndez-Ju\u00e1rez, G., Ronco, P. & Jha, V. Personalized treatment of PLA2R-related membranous nephropathy. Clin. J. Am. Soc. Nephrol. 18, 530\u2013532 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"980_CR175","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","volume":"83","author":"MA Podest\u00e0","year":"2024","unstructured":"Podest\u00e0, M. A. et al. Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series. Am. J. Kidney Dis. 83, 340\u2013349.e1 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"980_CR176","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti, P. et al. Rituximab in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1416\u20131425 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR177","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.kint.2021.11.001","volume":"101","author":"T Stehl\u00e9","year":"2022","unstructured":"Stehl\u00e9, T. et al. Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression. Kidney Int. 101, 416\u2013418 (2022).","journal-title":"Kidney Int."},{"key":"980_CR178","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.ekir.2024.06.018","volume":"9","author":"BH Rovin","year":"2024","unstructured":"Rovin, B. H. et al. Phase 1b\/2a study assessing the safety and efficacy of felzartamab in anti-phospholipase A2 receptor autoantibody-positive primary membranous nephropathy. Kidney Int. Rep. 9, 2635\u20132647 (2024).","journal-title":"Kidney Int. Rep."},{"key":"980_CR179","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000515087","volume":"1","author":"AS Geara","year":"2021","unstructured":"Geara, A. S., Bhoj, V. & Hogan, J. J. Bortezomib treatment for refractory PLA2R-positive membranous nephropathy. Glomerular Dis. 1, 40\u201343 (2021).","journal-title":"Glomerular Dis."},{"key":"980_CR180","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04154787 (2024)."},{"key":"980_CR181","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22134","volume":"39","author":"D Musone","year":"2024","unstructured":"Musone, D. et al. Therapeutic plasmapheresis in idiopathic membranous nephropathy anti-PLA2R-related: a case series. J. Clin. Apher. 39, e22134 (2024).","journal-title":"J. Clin. Apher."},{"key":"980_CR182","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/jpm14030249","volume":"14","author":"H Naciri Bennani","year":"2024","unstructured":"Naciri Bennani, H. et al. Is there a place for apheresis in the management of idiopathic membranous nephropathy? A report of three cases and literature review. J. Pers. Med. 14, 249 (2024).","journal-title":"J. Pers. Med."},{"key":"980_CR183","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/eci.12545","volume":"45","author":"J M\u00fcller-Deile","year":"2015","unstructured":"M\u00fcller-Deile, J., Schiffer, L., Hiss, M., Haller, H. & Schiffer, M. A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. Eur. J. Clin. Invest. 45, 1260\u20131269 (2015).","journal-title":"Eur. J. Clin. Invest."},{"key":"980_CR184","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/jca.21949","volume":"37","author":"P Hamilton","year":"2022","unstructured":"Hamilton, P. et al. Peptide GAM immunoadsorption in anti-PLA2R positive autoimmune membranous nephropathy. The PRISM trial. J. Clin. Apher. 37, 40\u201353 (2022).","journal-title":"J. Clin. Apher."},{"key":"980_CR185","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06690359 (2024)."},{"key":"980_CR186","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.kint.2024.01.021","volume":"105","author":"L Seifert","year":"2024","unstructured":"Seifert, L. et al. An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells. Kidney Int. 105, 886\u2013889 (2024).","journal-title":"Kidney Int."},{"key":"980_CR187","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2016010050","volume":"28","author":"E Hoxha","year":"2017","unstructured":"Hoxha, E. et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J. Am. Soc. Nephrol. 28, 520\u2013531 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"980_CR188","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.kint.2020.01.037","volume":"97","author":"WG Couser","year":"2020","unstructured":"Couser, W. G. The pathogenesis of human membranous nephropathy: we are (almost) there. Kidney Int. 97, 849\u2013852 (2020).","journal-title":"Kidney Int."},{"key":"980_CR189","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/j.1460-2075.1993.tb05878.x","volume":"12","author":"K Sano","year":"1993","unstructured":"Sano, K. et al. Protocadherins: a large family of cadherin-related molecules in central nervous system. EMBO J. 12, 2249\u20132256 (1993).","journal-title":"EMBO J."},{"key":"980_CR190","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0955-0674(02)00365-4","volume":"14","author":"M Frank","year":"2002","unstructured":"Frank, M. & Kemler, R. Protocadherins. Curr. Opin. Cell Biol. 14, 557\u2013562 (2002).","journal-title":"Curr. Opin. Cell Biol."},{"key":"980_CR191","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1101\/gad.14.9.1146","volume":"14","author":"DB Constam","year":"2000","unstructured":"Constam, D. B. & Robertson, E. J. SPC4\/PACE4 regulates a TGF\u03b2 signaling network during axis formation. Genes Dev. 14, 1146\u20131155 (2000).","journal-title":"Genes Dev."},{"key":"980_CR192","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1080\/0886022X.2018.1456457","volume":"40","author":"S Ren","year":"2018","unstructured":"Ren, S. et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren. Fail. 40, 306\u2013313 (2018).","journal-title":"Ren. Fail."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00980-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00980-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00980-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T12:03:33Z","timestamp":1758110613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00980-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":192,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["980"],"URL":"https:\/\/doi.org\/10.1038\/s41581-025-00980-z","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"17 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}